Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 357

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 357
---
        – |   |     |   |        – |   |
| Exercised                                |     |   | (2,361,865 | ) |     |   |        – |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Lapsed                                   |     |   |       (163 | ) |     |   |        – |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Warrant inducement May 2024              |     |   |          – |   |     |   |  931,585 |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| As at June 30, 2024 (unaudited)          |     |   |  1,824,198 |   |     |   |  931,585 |     |   |        – |   |     |   |        – |   |     |   |        – |   |

The Series A, Series
B and Series C warrants are exercisable on an ‘alternative cashless basis’ effectively allowing the holders to exercise for
nil consideration.

Ordinary and deferred
shares were recorded as equity.

| F-17 |

| Schedule of ordinary and deferred 
 shares                            |     |                                                         |     |               |     |               |     |               |     |                 |     |                     |
| 2024                              |     |                                                         |     |      Ordinary 
 Shares Number |     |  ‘A’ Deferred 
 Shares Number |     |  ‘B’ Deferred 
        Shares 
        Number |     |           Share 
         Price £ |     |               Total 
 consideration £’000 |
| At January 1, 2024                |     |                                                         |     | 1,189,577,722 |     |     1,000,001 |     | 4,063,321,418 |     |                 |     |                     |
| February to May 2024              |     | Exercise pre-funded warrants                            |     |   944,746,000 |     |             – |     |             – |     |          0.0040 |     |               3,732 |
| February to May 2024              |     | Exercise Series E & F